Previous 10 | Next 10 |
WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securitie...
It has been a tough 2020 so far for Minerva Neurosciences ( NERV ), with some bad news from one of its phase 3 programs sending the stock down. This article takes a look at what has happened and what is ahead for the company. Data by YCharts Figure 1: Year-to-date trading of NERV. The...
Image source: The Motley Fool. Minerva Neurosciences (NASDAQ: NERV) Q2 2020 Earnings Call Aug 03, 2020 , 8:30 a.m. ET Operator Continue reading
Minerva Neurosciences, Inc. (NERV) Q2 2020 Earnings Conference Call August 03, 2020 08:30 A.M. ET Company Participants William Boni - VP, IR & Corporate Communications Remy Luthringer - Executive Chairman and CEO Geoff Race - EVP, CFO and Chief Business Officer Conference ...
Minerva Neurosciences ( NERV +3.9% ) Q2 results : Collaborative revenue: $41.2M compared to nil last year; R&D Expense: $5.8M (-31%); G&A: $5.9M (+29%); Net income of $29.5M vs. loss of $12.5M, a year ago. More news on: Minerva Neurosciences, Inc., Earnings news and comme...
Minerva Neurosciences (NASDAQ: NERV ) : Q2 EPS of $0.73 may not be comparable to consensus of -$0.29. More news on: Minerva Neurosciences, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the qu...
Management to host conference call WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will r...
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass., Jul...
Markets have settled and recovered from the initial shock of the coronavirus spread and the response of governments around the US and the world to lock down the economy. But while the major US indices have approached, if not quite matched, the fabled v-shaped recovery, there are still plenty o...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...